Table 2. Loss of p19arf cooperates with v-rasHa in malignant conversion.
Normal Skin | Papilloma | Carcinoma | Total | Conversion rate | |
Lenti-GFP/v-rasHa | 0 | 5 | 0 | 5 | 0% |
Lenti-ΔNp63α/v-rasHa | 0 | 0 | 5 | 5 | 100% |
p19arf null/v-rasHa | 0 | 1 | 9 | 10 | 90% |
p19arf null/Lenti-ΔNp63α/v-rasHa | 0 | 0 | 10 | 10 | 100% |
Tumor incidence and conversion rate of grafted p19arf null keratinocytes are presented at 5 weeks post-grafting. Tumor phenotypes were confirmed histologically.